Oncotarget: An Open-Access Journal Disseminating Important Information On Oncology And More

Oncotarget is a peer-reviewed, open access journal that is published twice weekly. The bio-medical journal initially only published articles based on research on all areas of oncology. It has now become so widely embraced by the health care community that it now offers articles on health topics beyond oncology. Established in 2010, Oncotarget is a production of Impact Journals. This valuable medical resource has as its editors-in-chief noted researchers and educators Mikhail Blagosklonny and Andrei Gudkov. Visit Oncotarget’s profile page at Facebook.

The journal is indexed and abstracted in BIOSIS Previews, Scopus, Science Citation Index Expanded and Index Medicus/PubMed. Between 2011 and 2016, Oncotarget was ranked as one of the top oncology journals annually. It has an Impact Factor of 5.168. Initially published once weekly, Oncotarget has risen so much in impact, quality, volume and importance it is now published on Tuesday and Friday each week. This increase is designed to accelerate the publication’s dissemination of important scientific information. Accepted papers will be released to PubMed directly and quickly in their final paginated permanent form.

The editorial board of Oncotarget includes Nobel Prize winner Andrew V. Schally and former Cancer Research editor-in-chief Carlo M. Croce. Together the men have published more than 37 well-received papers in the journal. According to MEDLINE, Oncotarget plays a major role in sharing papers on important basic science research and has high ethical guidelines and editorial practices making it one of the field of oncology’s most important research journals. It has featured groundbreaking articles by some of the top scientists and researchers in oncology. Learn more at researchgate.net

The newly expanded version of Oncotarget now accepts papers on Cardiology, Cell Biology, Endocrinology, Metabolism, Neuroscience, all areas of Pharmacology and much more. An outstanding journal, Oncotarget publishes more documents on Oncology than any other journal. The publication performs a very useful function for medical professionals and researchers working on cancer research and medicine in general. It receives strong support from the NIH and investigators working in oncology. Printed copies of the online journal are made available to people upon request.

Download: http://endnote.com/downloads/style/oncotarget

In its 7 years of existence Oncotarget has had a significant impact on cancer research.

How Mikhail Blagosklonny’s Oncotarget Has Helped People

While Oncotarget has done a lot of good for people who are in different situations, the things that Mikhail Blagosklonny has done for cancer treatment have been even more numerous. He works hard on the cancer treatment options that he has and he always tries to find more so that he can help all of his patients. Mikhail Blagosklonny is consistently confident that he will be able to provide people with the help that they need and that he will be able to come up with treatments that will help people who are suffering from cancer and who need to be able to feel better about the things that they are doing.For Mikhail Blagosklonny, cancer treatment is something that he is passionate about. He likes to help people and he likes to make sure that they are as healthy as possible. By treating cancer, he knows that he can make a difference and that he can actually help people who have issues in their own lives.

He has been able to provide people with all of the options that they need and has been helping them for years but has recently come up with new ideas that will bring change to the cancer treatment world.One of the most important things that he has done is created Oncotarget. This is the location in which people are able to talk about the different things that they have found in their specialized areas. He wants to make sure that he can figure out what is going on in their lives and what they have found for the different diseases that they work with. Mikhail Blagosklonny knows a lot about cancer treatment and wants to share his knowledge. He also thinks that the knowledge that other doctors have will be helpful for him so that he can learn more about what is going on in the different treatment areas.

By creating Oncotarget, Mikhail Blagosklonny has set himself up to make things better and to connect with other doctors. In fact, the publication was the result of being able to make things better for everyone and for the different things that are going on in the areas that Mikhail Blagosklonny is in.He has tried to make sure that he will be able to provide people with all of the things that they need and the treatment option of rejuvenation therapy has been helpful.By using rejuvenation therapy, Mikhail Blagosklonny is able to help people who have compromised immune systems. That is one of the biggest risks in cancer and Mikhail Blagosklonny wants to combat it. He plans to continue to use rejuvenation therapy to help people get the best immune system possible and to help them feel better about the things that they are doing with their cancer treatment. Mikhail Blagosklonny is dedicated to showing people what they can do and how they will be able to feel no matter what type of cancer they are trying to fight to get rid of.

Eric Lefkofsky and Tempus

Born in Southfield, Michigan, Eric Lefkofsky, a self-made billionaire, emerged from somewhat humble beginnings. After he graduated from the University of Michigan in 1991, he sold carpet, and in 1993 received his Juris Doctor at the University of Michigan Law School. After law school, Lefkofsky had many ventures, some that eventually led to great wealth. One of those ventures is a very familiar company called Groupon, in which he became the CEO. According to Forbes, Lefkofsky stepped down as CEO and became chairman in 2015. In 2016, Lefkofsky co-founded the technology company, Tempus.

Tempus is not just any technology company. Lefkofsky’s motivation for Tempus was born when a loved one was suffering from cancer. Lefkofsky saw up close and personal a need for physicians to better treat their patients, and technology was the answer. His experience prompted him to use his platform to bring this technology to physicians and their patients.

Tempus has built a software system that helps physicians to make real-time decisions based upon data from genomic sequencing services. When a physician has access to this amazing advanced technology that analyzes molecular and therapeutic data, their patients have answers that would otherwise cost them precious time. This data allows doctors to personalizes care for each patient with speed, precision, and accuracy. Eric Lefkofsky, with the help of his team, has made this technology available, and has already began to help save lives and give people hope.

Lefkofsky is also quite the philanthropist. Lefkofsky Family Foundation (LFF) was founded by him and his wife, Liz, in order to enhance the well-being of others, particularly children. Their are four main focuses with LFF which are education, basic human rights, medical advancement, and arts and culture. The Lefkofsky’s believe that education is a basic human right, and LFF helps to make available formidable education for people in their community. The foundation also supports medical advancement, of cancer in particular, since it has affected the Lefkofsky’s personally. LFF also supports the arts and culture in their community with the belief that cities and communities thrive with its richness. LFF is located in Chicago, IL, where the Lefkofsky’s live.

Entrepreneur, philanthropist, self-made billionaire, husband and father, Eric Lefkofsky has come a long way from selling carpet at the University of Michigan. His contributions to technology in the realm of modern medicine has already helped many people. It will be amazing to see what he accomplishes I the next few years with Tempus and other ventures he has yet to unveil. Lefkofsky may be someone whom contributes to the longevity of life for some, and may even save the lives of people who would not have the opportunity if it had not been for the creation of Tempus.

More information for Eric Lefkofksy: http://chicagoinno.streetwise.co/2016/07/22/eric-lefkofskys-next-move-curing-cancer-at-tempus/